The present study was aimed to prove the hypothesis that inactivation of the TGF-β signaling pathway in the tumor microenvironment exerts a positive synergistic effect on PD-1 antibody treatment combined with RFA against PLC. The gene discussed is TGFB1; the disease is neoplasm.